Table 1.

Clinical and diagnostic characteristics of pemphigus vulgaris patients.

							IIF§		ELISA¶
Patient no.	Sex	Age of onset	Clinical profile	Severity*	Histo†	DIF‡	IgG	IgG4	Dsg1	Dsg3
001	M	50	Skin, oral, nasal pharyngeal	Severe	+	+	640	1260	118	410
002	M	52	Skin, oral, penile, larynx	Severe	+	+	320	1260	130	359
003	F	69	Oral, pharyngeal, oesophageal, nail	Severe	+	+	1260	2560	55	330
004	M	70	Oral, nasal, larynx	Moderately severe	+	+	320	1280	36	437
005	F	63	Skin, oral, oesophageal	Moderately severe	+	+	160	640	315	279
006	F	53	Oral, pharyngeal, ocular	Moderately severe	+	+	160	320	29	283
007	F	54	Skin, nasal, oesophageal, nail	Severe	+	+	2560	2560	310	317
008	M	51	Skin, pharyngeal, anal	Moderately severe	+	+	640	1280	258	188
009	F	60	Skin, nasal, oesophageal	Severe	+	+	640	640	149	210
010	M	54	Oral, pharyngeal, penile, larynx	Severe	+	+	320	640	81	286
011	F	53	Skin, ocular, anal, larynx	Severe	+	+	640	1280	338	276
012	F	51	Oral, nasal	Moderately severe	+	+	320	640	73	345
013	F	55	Skin, oesophageal, larynx, nail	Severe	+	+	2560	2560	301	336
014	M	50	Oral, pharyngeal	Moderately severe	+	+	160	160	86	377
015	M	66	Skin, penile, ocular	Severe	+	+	320	1280	259	162

^*Severity of disease.

^†Histology, biopsy of lesion demonstrated suprabasilar acantholysis.

^‡Direct immunofluorescence, deposition of immunoglobulin G (IgG) on the keratinocyte cell surface of perilesional tissue.

^§Prior to initiation of therapy titre of pemphigus autoantibody determined by indirect immunofluorescence using monkey oesophagus. Titre of total IgG and IgG4 reported.

^¶Enzyme-linked immunosorbent assay (ELISA) using recombinant dsg peptide in commercially available plates. Titre for desmoglein 1 (Dsg1) and Dsg3 provided.